Endo eyes the future and shuns shortages

Endo has no appetite for “going back and redeveloping” injectable drugs that are in short supply, because the firm’s focus remains on higher-value “technically-challenging products” and paragraph IV patent-challenge opportunities, according to the company’s president and chief executive officer, Paul Campanelli.